Interestingly, NicheNet analysis predicted TGFB1 as the most highly ranked ligand expressed by angiogenic ECs, that likely affects the differential transcriptome in myeloid cells (Supplementary Fig. 7i), indicating that TGFB1 might indeed be active in modulating myeloid cells, and possibly TAMs, in the tumor. Here, TGFB1 is linked to neoplasm.